Insilico expands Tenacia CNS AI deal to $94.75 million
CURRENT BRIEF VERSION: Insilico Medicine said it has expanded its central nervous system collaboration with Tenacia Biotechnology in a deal worth up to $94.75 million, adding a second AI-designed drug discovery program for neurological diseases. The March 26 announcement builds on a March 2025 partnership focused on small-molecule inhibitors with blood-brain barrier permeability for CNS treatment. Under the new agreement, Insilico will use its Pharma.AI platform with Tenacia’s CNS expertise and proprietary data to advance an additional candidate to the preclinical candidate stage, with Insilico eligible for near-term and milestone payments. (prnewswire.com)
Why it matters: For veterinary professionals, this is another signal that AI-enabled drug discovery is moving beyond pilot projects and into repeat collaborations around hard-to-treat neurologic disease. While the Tenacia deal is focused on human CNS disorders, the same bottlenecks it aims to address, including target selection, blood-brain barrier penetration, and late-stage attrition, are also familiar in animal health. Insilico has been broadening its AI-partnering footprint in CNS and adjacent areas, and its larger pharma tie-ups also suggest sustained confidence in platform-based discovery models: in addition to CNS deals with China Medical System and Hygtia, the company signed a multi-program collaboration with Eli Lilly worth up to about $2.75 billion, including $115 million upfront, to use Pharma.AI across multiple therapeutic areas. (prnewswire.com; pharmashots.com)
What to watch: Watch for disclosure of the target, any preclinical data from the first Tenacia program, and whether Insilico begins extending similar AI-discovery partnerships into veterinary medicine or comparative neurology. Lilly’s deal structure is also worth watching as a benchmark: it gave the pharma company exclusive global rights to develop, manufacture, and commercialize select preclinical oral candidates, alongside multiple R&D programs built around Lilly-selected targets. (prnewswire.com; pharmashots.com)